DE-ESCALATION OF TYROSINE KINASE INHIBITOR THERAPY IS SAFE IN CHRONIC MYELOID LEUKAEMIA IN DURABLE MOLECULAR RESPONSE (>= MR3 FOR >= 12 MONTHS): INITIAL RESULTS IN THE BRITISH DESTINY STUDY

File(s)

75.pdf (56.81 KB)

Published version

Show more

Author(s)

Clark, R

Polydoros, F

Apperley, J

Pocock, C

Smith, G

more

Type

Conference Paper

Date Issued

2016-06-01

Date Acceptance

2016-01-01

Citation

Haematologica, 2016, 101 (Suppl 1), pp.60-60

URI

http://hdl.handle.net/10044/1/40113

DOI

http://www.haematologica.org/content/101/s1/1

ISSN

0390-6078

Publisher

Ferrata Storti Foundation

Start Page

60

End Page

60

Journal / Book Title

Haematologica

Volume

101

Issue

Suppl 1

Copyright Statement

DE-ESCALATION OF TYROSINE KINASE INHIBITOR THERAPY IS SAFE IN CHRONIC MYELOID LEUKAEMIA IN DURABLE MOLECULAR RESPONSE (>= MR3 FOR >= 12 MONTHS): INITIAL RESULTS IN THE BRITISH DESTINY STUDY. Haematologica vol. 101 no. s1 60. ©2016 by Ferrata-Storti Foundation/European Hematology Association. All rights reserved.

Sponsor

Bristol Myers Squibb

National Institute for Health Research

Leuka

Grant Number

n/a

NF-SI-0611-10275

N/A

Source

21st Congress of the European Hematology Association

Subjects

Science & Technology

Life Sciences & Biomedicine

Hematology

Immunology

1102 Cardiovascular Medicine And Haematology

Publication Status

Published

Start Date

2016-06-09

Finish Date

2016-06-12

Coverage Spatial

Copenhagen, Denmark